Streamlining Medicaid Epclusa Prior Authorization

Epclusa: A High-Volume Target for Medicaid Prior Authorization

Epclusa, a direct-acting antiviral combination of sofosbuvir and velpatasvir, is indicated for adults and pediatric patients aged 3 years and older with chronic Hepatitis C virus (HCV) genotypes 1-6. Due to its high cost and specialized nature, Epclusa is consistently subject to prior authorization requirements across state Medicaid programs and their contracted managed care organizations (MCOs). These requirements are designed to ensure medical necessity and adherence to specific treatment guidelines.

Understanding Medicaid's Dual Prior Authorization Pathways

Medicaid prior authorization for Epclusa can follow one of two primary pathways depending on the state and member enrollment. For Fee-for-Service (FFS) beneficiaries, PA requests route directly to the state Medicaid agency's fiscal agent. Conversely, the vast majority of Medicaid beneficiaries are enrolled in managed care plans, where prior authorization workflows are administered by the specific Medicaid Managed Care Organization (MCO) responsible for their benefits, such as Centene subsidiaries, Molina, or UHC Community Plan. This state-by-state and MCO-specific variation introduces significant administrative complexity.

Klivira's Optimized Approach to Medicaid Epclusa PA

Klivira's platform is engineered to navigate the intricate landscape of Medicaid Epclusa prior authorization. Our system intelligently identifies the correct delivery model—whether Fee-for-Service or managed care—and, for MCOs, directs submissions to the appropriate payer portal or X12 278 endpoint. We integrate state Medicaid agency policy libraries and MCO-specific criteria, ensuring that all submissions are aligned with the medical necessity guidelines for Epclusa, including any applicable step therapy or quantity limit considerations, where supported by the payer.

CMS-0057-F and Medicaid Managed Care for Specialty Drugs

Medicaid managed care organizations (MCOs) are designated as impacted payers under CMS-0057-F, which mandates specific prior authorization decision timeframes—72 hours for standard requests and 24 hours for expedited requests—and requires the implementation of FHIR-based Prior Authorization APIs on a phased timeline. While traditional FFS Medicaid is less directly impacted by the API requirements, these interoperability provisions are driving broader improvements in the electronic prior authorization (ePA) ecosystem. Klivira supports these evolving standards, including SMART on FHIR, to streamline the Epclusa PA process.

Common Challenges in Medicaid Epclusa Prior Authorization

• **Varying Policy Criteria:** Each state Medicaid agency and MCO may have distinct medical necessity criteria, formulary tiers, or step therapy requirements for Epclusa.
• **Diverse Submission Channels:** Requiring manual submission across multiple state portals, individual MCO provider portals, or limited X12 278 support.
• **Documentation Burden:** Gathering and submitting comprehensive clinical documentation to justify Epclusa's medical necessity for specific HCV genotypes.
• **Tracking and Follow-up:** Monitoring the status of numerous Epclusa PA requests across disparate systems and ensuring timely appeals for denials.
• **Payer-Specific Nuances:** Understanding the specific PBM or specialty pharmacy partners that handle Epclusa for a given Medicaid MCO or state program.

Accelerating Access to HCV Treatment with Klivira

Klivira empowers revenue cycle teams and prior authorization coordinators to overcome the inherent complexities of Medicaid Epclusa PA. By automating the identification of the correct payer pathway, leveraging up-to-date policy libraries, and facilitating electronic submission via appropriate channels (e.g., X12 278, payer portals), Klivira significantly reduces manual effort, accelerates decision times, and improves the likelihood of first-pass approvals for Epclusa. This ensures patients receive timely access to life-changing Hepatitis C treatment while optimizing your organization's financial performance.